XML 67 R34.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Summary of Significant Accounting Policies (Details 6) (USD $) | 3 Months Ended | 12 Months Ended | 1 Months Ended
--- | --- | --- | ---
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2014 | Dec. 31, 2014
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | $ 963,300,000 xncr_RevenueRecognitionMilestoneMethodPending |  |  |  |  |  |  |  | $ 963,300,000 xncr_RevenueRecognitionMilestoneMethodPending |  |  |  | $ 963,300,000 xncr_RevenueRecognitionMilestoneMethodPending
Revenue recognized | 5,664,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 848,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 824,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 2,184,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 1,745,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 3,161,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 3,921,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 1,345,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 9,520,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 10,172,000 xncr_CollaborationsLicensesAndMilestonesRevenue | 9,524,000 xncr_CollaborationsLicensesAndMilestonesRevenue |  |
Accounts receivable | 2,966,000 us-gaap_AccountsReceivableNetCurrent |  |  |  | 59,000 us-gaap_AccountsReceivableNetCurrent |  |  |  | 2,966,000 us-gaap_AccountsReceivableNetCurrent | 59,000 us-gaap_AccountsReceivableNetCurrent |  |  | 2,966,000 us-gaap_AccountsReceivableNetCurrent
Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 181,800,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 181,800,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 181,800,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 426,000,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 426,000,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 426,000,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 355,500,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 355,500,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 355,500,000 xncr_RevenueRecognitionMilestoneMethodPending / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
UNITED STATES |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 8,600,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = country_US | 4,200,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = country_US | 4,400,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = country_US |  |
Non United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 900,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = xncr_NonUnitedStatesMember | 6,000,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = xncr_NonUnitedStatesMember | 5,100,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_StatementGeographicalAxis = xncr_NonUnitedStatesMember |  |
Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 6,900,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_AmgenIncMember | 2,200,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_AmgenIncMember | 1,800,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_AmgenIncMember | 5,200,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_AmgenIncMember |
MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 299,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember |  |  |  |  |  |  |  | 299,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember |  |  |  | 299,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember
Revenue recognized |  |  |  |  |  |  |  |  | 0 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember | 3,000,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember | 2,000,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember |  |
Accounts receivable |  |  |  |  | 100,000 us-gaap_AccountsReceivableNetCurrent / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember |  |  |  |  | 100,000 us-gaap_AccountsReceivableNetCurrent / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember |  |  |
MorphoSys | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 62,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 62,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 62,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
MorphoSys | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 187,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 187,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 187,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
MorphoSys | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 50,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 50,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 50,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MorphoSysMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 399,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember |  |  |  |  |  |  |  | 399,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember |  |  |  | 399,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember
Alexion Pharmaceuticals, Inc. | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
Alexion Pharmaceuticals, Inc. | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 168,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 168,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 168,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
Alexion Pharmaceuticals, Inc. | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 180,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 180,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 180,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_AlexionPharmaceuticalsIncMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
BI |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 27,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember |  |  |  |  |  |  |  | 27,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember |  |  |  | 27,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember
BI | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 9,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 9,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 9,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
BI | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
BI | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 12,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 12,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 12,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_BIMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
Merck Sharp & Dohme Corp. |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 9,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember |  |  |  |  |  |  |  | 9,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember |  |  |  | 9,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember
Revenue recognized |  |  |  | 500,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember |  |  |  |  | 600,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember | 1,000,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember |  |  |
Merck Sharp & Dohme Corp. | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 3,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 3,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 3,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
Merck Sharp & Dohme Corp. | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_MerckSharpAndDohmeCorpMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
Novo Nordisk |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 167,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember |  |  |  |  |  |  |  | 167,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember |  |  |  | 167,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember
Accounts receivable | 3,000,000 us-gaap_AccountsReceivableNetCurrent / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember |  |  |  |  |  |  |  | 3,000,000 us-gaap_AccountsReceivableNetCurrent / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember |  |  |  | 3,000,000 us-gaap_AccountsReceivableNetCurrent / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember
Novo Nordisk | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 36,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 36,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 36,300,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
Novo Nordisk | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  |  |  |  |  | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember |  |  |  | 51,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember
Novo Nordisk | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 80,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 80,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 80,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_NovoNordiskMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 10,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember |  |  |  |  |  |  |  | 10,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember |  |  |  | 10,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember
Revenue recognized |  |  |  |  |  |  |  |  | 0 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_JanssenMember | 0 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_JanssenMember | 1,400,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_JanssenMember |  |
Janssen | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  |  |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember
Janssen | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  |  |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_JanssenMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember
2009 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 15,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  |  |  |  |  | 15,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  | 15,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 1,800,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |
2009 Research License and Commercialization Agreement | CSL Limited | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  |  |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  | 6,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember
2009 Research License and Commercialization Agreement | CSL Limited | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  |  |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember
2009 Research License and Commercialization Agreement | CSL Limited | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 5,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  |  |  |  |  | 5,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember |  |  |  | 5,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_ResearchLicenseAndCommercialization2009AgreementMember
May 2013 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 36,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  |  |  |  |  | 36,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  | 36,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember
Revenue recognized |  |  |  |  |  |  |  |  | 700,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember | 2,400,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember | 1,800,000 xncr_CollaborationsLicensesAndMilestonesRevenue / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |
May 2013 Research License and Commercialization Agreement | CSL Limited | Development-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 8,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  |  |  |  |  | 8,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  | 8,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_DevelopmentBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember
May 2013 Research License and Commercialization Agreement | CSL Limited | Regulatory-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  |  |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  | 4,000,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_RegulatoryBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember
May 2013 Research License and Commercialization Agreement | CSL Limited | Sales-based |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |
Total | $ 24,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  |  |  |  |  | $ 24,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember |  |  |  | $ 24,500,000 xncr_RevenueRecognitionMilestoneMethodPending / us-gaap_CounterpartyNameAxis = xncr_CSLLimitedMember / xncr_PotentialMilestonesTypeAxis = xncr_SalesBasedMilestonesMember / us-gaap_TypeOfArrangementAxis = xncr_May2013ResearchLicenseAndCommercializationAgreementMember

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the revenue earned during the period pertaining to collaborations, licenses and milestones. + References No definition available. + Details
Name: | xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_BIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_JanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=xncr_NonUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_May2013ResearchLicenseAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |